Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Auteurs : Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F, + collaborators (among others :, Piccart-Gebhart M
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 371-382

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Auteurs : Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart-Gebhart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 336-349

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Auteurs : Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M
Année : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 361-370

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Auteurs : Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber Rd, Dowsett M, Leyland-Jones B, Piccart-Gebhart M, de Azambuja E
Année : 2019
Journal : Anticancer Res
Volume : 39
Pages : 797-802

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

Auteurs : Pondé N, Gelber Rd, Piccart-Gebhart M
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 1

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Auteurs : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart-Gebhart M, Loi S, de Azambuja E
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Année : 2019
Journal : Eur J Cancer
Volume : 114
Pages : 55-66

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Auteurs : Pondé N, Aftimos P, Piccart-Gebhart M
Année : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pages : 37

ER+/HER2+ breast cancer: are we really de-escalating?

Auteurs : de Azambuja E, Piccart-Gebhart M
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 875-877

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

Auteurs : Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1541-1557

Systemic treatment of patients with early breast cancer: recent updates and state of the art.

Auteurs : Caparica R, Brandão M, Piccart-Gebhart M
Année : 2019
Journal : Breast
Volume : 48 Suppl 1
Pages : S7-S20

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37.298 women with early breast cancer in 26 randomised trials.

Auteurs : Early Breast Cancer Trialists Collaborative Group, + collaborators (among others :, Philippson C, Larsimont D, Nogaret JM, Piccart-Gebhart M
Année : 2019
Journal : Lancet
Volume : 393
Pages : 1440-1452

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1018

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1180

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Auteurs : Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1181

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Auteurs : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Auteurs : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : EBioMedicine
Volume : 39
Pages : 226-238

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Auteurs : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316